On this page
TB-500 Evidence: Human Data, Safety, and Marketing Claims
TB-500 is commonly discussed for recovery and soft-tissue healing, but the marketed fragment and the broader thymosin beta-4 literature are not interchangeable.1
Bottom line
FDA reports that it has not identified human exposure data for drug products containing the thymosin beta-4 fragment used in TB-500 marketing.1 That evidence gap does not support benefit, dosing, or safety claims.1
What the name does not establish
“TB-500” may be used commercially for a fragment associated with thymosin beta-4.1 A paper about the full protein, an animal model, or a laboratory pathway does not automatically apply to a marketed vial, formulation, route, dose, or human outcome.1Preclinical evidence only; human benefit and safety are not established.
Claim-by-claim evidence check
| Claim | Evidence question | Evidence status |
|---|---|---|
| Tendon or muscle healing | Controlled human trials of the marketed fragment? | Not established |
| Faster recovery | Validated patient-centered outcomes? | Not established |
| Safe injection | Product-specific sterility, dose, pharmacology and adverse-event data? | Not established |
Questions a source must answer
Safety and interpretation boundary
This page does not recommend purchase, injection, or use.1 A research-use-only label, certificate of analysis, or seller statement cannot establish suitability for human use.1
Sources and methods
- FDA: bulk substances that may present significant safety risks (reopened 2026-08-22)
- FDA Drugs@FDA database (reopened 2026-08-22)
- ClinicalTrials.gov (reopened 2026-08-22)
Evidence and status are separate questions
| Layer | Question | Common category error |
|---|---|---|
| Product status | Is the exact product approved, compounded, investigational or sold for research? | Treating a facility, ingredient or trial as product approval |
| Human evidence | Do trials match the molecule, route, population and claimed outcome? | Generalizing from animals, another peptide or another route |
| Quality | What identity, batch, sterility and endotoxin evidence exists? | Using analytical purity as a synonym for sterile or safe |
| Personal decision | What established alternatives, risks and monitoring questions matter? | Letting an online claim replace qualified care |
This publication provides no dose, cycle, injection technique, seller ranking or procurement path for unapproved investigational products.1
Thymosin beta-4 research is not a TB-500 product claim
| Evidence label | What it may describe | Transfer that is not justified |
|---|---|---|
| Thymosin beta-4 biology | A naturally occurring peptide and experimental pathways | Identity or effect of every product sold as “TB-500” |
| Animal injury model | A preclinical question under controlled conditions | Human tendon recovery, performance or return-to-sport benefit |
| Human research on a related formulation | That exact product, route, population and endpoint | A gray-market fragment, stack or injectable protocol |
| Seller COA | Only the fields and batch tested, if authentic and traceable | Sterility, clinical benefit, legality or safe administration |
Searches and marketing should use exact molecular terms. “TB-500” is not a shortcut that makes thymosin beta-4 literature product-specific, and this page supplies no dose, cycle or purchase path.1
Claim-linked evidence notes
Read the linked sources in context: a source’s population, outcome and limitations determine where it applies. Its inclusion does not imply endorsement of this publication or prove an individual result.